Get the Stockscreener App
4.6152
1.21%
0.0551
Pluri Inc stock is traded at $4.6152, with a volume of 44,698.
It is up +1.21% in the last 24 hours and down -11.08% over the past month.
Pluri Inc is a biotechnology company, that creates cell-based products for commercial use and is pioneering a biotech revolution that promotes wellbeing and sustainability. The company's technology platform developed a three-dimensional, or 3D, technology platform for cell expansion with an industrial scale in-house Good Manufacturing Practice, or GMP, cell manufacturing facility. It uses its technology in the field of regenerative medicine, food tech and agricultural technology or agtech.
See More
Previous Close:
$4.5601
Open:
$4.73
24h Volume:
44,698
Relative Volume:
3.13
Market Cap:
$24.94M
Revenue:
$326.00K
Net Income/Loss:
$-20.89M
P/E Ratio:
-5.9938
EPS:
-0.77
Net Cash Flow:
$-18.34M
1W Performance:
+0.37%
1M Performance:
-11.08%
6M Performance:
-19.74%
1Y Performance:
-2.22%
1-Day Range:
$4.332
$4.75
1-Week Range:
$4.332
$5.008
52-Week Range:
$3.7728
$8.48
Pluri Inc Stock (PLUR) Company Profile
Name
Pluri Inc
Sector
Industry
Phone
972-74-710-7171
Address
MATAM ADVANCED TECHNOLOGY PARK, HAIFA
Pluri Inc Stock (PLUR) Latest News
Pluri And Bar-Ilan University Partner To Advance MAIT Cell Therapy For Solid Tumors - Contract Pharma
Pluri Flat on Funding From Innovation Authority - Baystreet.ca
Pluri Collaborates with Bar-Ilan University to Advance - GlobeNewswire
Pluri Collaborates with Bar-Ilan University to Advance Cancer Immunotherapy for Solid Tumors, Supported by Israel Innovation Authority - StockTitan
Cell And Gene Therapy Contract Development And Manufacturing - openPR
Renaissance Technologies LLC Decreases Position in Pluri Inc. (NASDAQ:PLUR) - Defense World
(PLUR) Technical Pivots with Risk Controls - Stock Traders Daily
Plurilock (PLUR.V) lands $19 million deal, largest in their history - Equity.Guru
Pluri Inc. regains compliance with Nasdaq listing rules - Investing.com India
Pluri Inc. regains compliance with Nasdaq listing rules By Investing.com - Investing.com UK
TomTom (OTCMKTS:TMOAF) Short Interest Down 34.8% in September - Defense World
(PLUR) Proactive Strategies - Stock Traders Daily
The Plurilock (PLUR.V) rip is over: But is that the end of the play? - Equity.Guru
Plurilock’s Behavioral Biometrics: Next-Gen Cybersecurity with Scott Meyers - The Deep Dive
Investor Summit August 2024 Presentations Now Accessible for On-Demand Viewing - Yahoo Finance
Plurilock Security joins forces with cloud platform for data protection - Mugglehead
Cell Therapy Manufacturing Market Size Projected to Reach - GlobeNewswire
Ever After Foods receives $10 million investment - Food Business News
Former CrowdStrike Director Reveals Plurilock’s Potential - The Deep Dive
Stem Cell Therapy Market Set to Skyrocket to $48.89 Billion by 2033, Fueled by 13.2% CAGR - BioSpace
Pluri Unveils Proprietary 3D Cell Expansion Technology - Contract Pharma
Cyber Warfare: Ex-CIA Officer Warns of New Global Conflict, With Bryan Cunningham of Plurilock Security - The Deep Dive
Pluri (NASDAQ:PLUR) versus Tarsus Pharmaceuticals (NASDAQ:TARS) Critical Review - American Banking and Market News
(PLUR) Trading Advice - Stock Traders Daily
Critical Survey: Tevogen Bio (NASDAQ:TVGN) versus Pluri (NASDAQ:PLUR) - Defense World
Spanish seafood processors slam plant-based seafood labeling practices; Steakholder Foods signs MoU with Sherry Herring - SeafoodSource
Spanish seafood processors slam plant-based seafood labeling practices; Tender Food products now in Clover locations - SeafoodSource
Pluri Inc. faces potential Nasdaq delisting over equity shortfall - Investing.com
Pluri Inc. faces potential Nasdaq delisting over equity shortfall By Investing.com - Investing.com Canada
400% Stock Surge: What’s Next for Plurilock Security? | Ali Hakimzadeh - The Deep Dive
Pluri enters deal to manufacture Kadimastem’s AstroRx for ALS - ALS News Today
Pluri signs tech transfer, manufacturing agreement with Kadimastem - TipRanks
Pluri’s CDMO To Manufacture Kadimastem’s Cell Therapy Candidates - Contract Pharma
Pluri’s CDMO Selected to Manufacture Kadimastem’s Novel Cell Therapy Product Candidates - Morningstar
(PLUR) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Joe Sexton: Enhancing Plurilock’s Vision with Decades of Experience - The Deep Dive
Contrasting Pluri (NASDAQ:PLUR) & Relay Therapeutics (NASDAQ:RLAY) - American Banking and Market News
Plurilock Appoints Palantir Senior Advisor To Company’s Industry Advisory Council - The Deep Dive
Critical Comparison: Pluri (NASDAQ:PLUR) & Relay Therapeutics (NASDAQ:RLAY) - Defense World
Pluri (NASDAQ:PLUR) Trading 0.3% Higher - Defense World
Pluristyx Announces License Agreement with Humacyte to Develop BioVascular Pancreas using iPSCs - Business Wire
Pluri Inc partners to boost global vegetable supply - Investing.com India
Pluri Inc partners to boost global vegetable supply By Investing.com - Investing.com Canada
Morgan Stanley raises TSMC shares target on strong demand outlook By Investing.com - Investing.com India
Seagate stock target raised, maintains Neutral stance on financial performance By Investing.com - Investing.com India
Strategic Agreement Sparks Market Interest In Pluri (PLUR) Stock - State Reviewer
Pluri Announces €1 Million Proof of Concept Agreement to Enhance Global Sustainable Vegetable Supply - StockTitan
Pluri announces proof of concept agreement with an agriculture corporation - TipRanks
Turnaround Tale: Why Plurilock (PLUR.V) sucked, and what it’s done to fix itself - Equity.Guru
BioCentriq Enhances Partnership With Pluristyx - Contract Pharma
Pluri Inc. appoints new CFO as current officer resigns By Investing.com - Investing.com South Africa
Pluri Inc Stock (PLUR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):